Low rates of contrast-induced nephropathy in patients with diabetes mellitus and chronic kidney
disease: PREDICT study
by V. Matarese
The PREDICT study [1] is the latest addition to a body of evidence on the renal safety of iodinated
contrast agents. In this randomized controlled trial (RCT), researchers from universities and
private clinics in the US and China did a head-to-head comparison of intravenously administered
Iodixanol-320 and Iopamidol-370, two well-studied nonionic contrast agents. Iodixanol is
iso-osmolar to blood (290 mOsm/kg H20, 320 mgI/ml) while iopamidol is hyperosmolar to blood (796
mOsm/kg H20, 370 mgI/ml); however, iopamidol is a low-osmolar contrast medium due to the existence
of contrast media of even greater osmolality.
